Ameritas Advisory Services’s Tandem Diabetes Care TNDM Stock Holding History

Ameritas Advisory Services’s Portfolio TNDM Stock Details TNDM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-50	Closed	-$607	–	2001
2025 Q3	$607	Hold	50	–	–	﹤0.01%	2085
2025 Q2	$932	Buy	+50	New	+$990	﹤0.01%	2635
2023 Q2	–	Sell	-485	Closed	-$19.3K	–	2345
2023 Q1	$19.3K	Buy	+485	New	+$20.1K	﹤0.01%	1662

Other funds holding TNDM

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Sessa Capital New York $5.98B AUM 99.85% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return

GKIM

GW&K Investment Management Boston, Massachusetts $12.8B AUM 48.82% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

PIM

Paradice Investment Management Denver, Colorado $627M AUM 43.41% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Ameritas Advisory Services's TNDM Position: Q4 2025 in Review

Ameritas Advisory Services sold out of Tandem Diabetes Care (TNDM) in Q4 2025, closing a stake of 50 shares — an estimated $607 sold.

Ameritas Advisory Services first reported a position in TNDM in Q1 2023 and held it in 3 quarters. The position peaked at $19.3K in Q1 2023. 268 funds tracked by Wall St. Rank hold TNDM as of Q4 2025.

Ameritas Advisory Services reported no remaining Tandem Diabetes Care position as of Q4 2025 after selling out during the quarter.
Ameritas Advisory Services sold 50 Tandem Diabetes Care shares in Q4 2025, an estimated $607.
Ameritas Advisory Services first reported a position in Tandem Diabetes Care in Q1 2023 and held it in 3 quarters.
Ameritas Advisory Services's Tandem Diabetes Care position peaked at $19.3K in Q1 2023.
268 funds tracked by Wall St. Rank held Tandem Diabetes Care as of Q4 2025.

Based on Ameritas Advisory Services's 13F filing for Q4 2025, filed 4 Feb 2026.